Investigation of the role of transporters on the hepatic elimination of an LAT1 selective inhibitor JPH203

Journal of Pharmaceutical Sciences

Volumn 102, Issue 9, 2013, Pages 3228-3238

  Toyoshima, Junko ^a   Kusuhara, Hiroyuki ^a   Wempe, Michael F ^b   Endou, Hitoshi ^c   Sugiyama, Yuichi ^d  

^a UNIVERSITY OF TOKYO   (Japan)

^b UNIVERSITY OF COLORADO   (United States)

^c J Pharma Co   (Japan)

^d RIKEN   (Japan)

Author keywords

ADME; Biliary excretion; Bioavailability; Cancer chemotherapy; Hepatocytes; Transporters

Indexed keywords

ANTINEOPLASTIC AGENT; JPH 203; MULTIDRUG RESISTANCE PROTEIN 2; RIFAMPICIN; UNCLASSIFIED DRUG;

ANIMAL TISSUE; ARTICLE; BLOOD FLOW VELOCITY; DRUG ELIMINATION; DRUG TRANSFORMATION; DRUG UPTAKE; HUMAN; HUMAN CELL; IN VITRO STUDY; LIQUID CHROMATOGRAPHY; LIVER CELL; LIVER CLEARANCE; MALE; MASS SPECTROMETRY; NONHUMAN; RAT;

ADME; BILIARY EXCRETION; BIOAVAILABILITY; CANCER CHEMOTHERAPY; HEPATOCYTES; TRANSPORTERS;

ANIMALS; ANTINEOPLASTIC AGENTS; BENZOXAZOLES; BILE; HEK293 CELLS; HEPATOCYTES; HUMANS; LARGE NEUTRAL AMINO ACID-TRANSPORTER 1; MALE; NEOPLASMS; RATS; RATS, SPRAGUE-DAWLEY; TYROSINE;

EID: 84881614360     PISSN: 00223549     EISSN: 15206017     Source Type: Journal    
DOI: 10.1002/jps.23601     Document Type: Article

References (33)

1. Kanai Y, Endou H. 2001. Heterodimeric amino acid transporters: Molecular biology and pathological and pharmacological relevance. Curr Drug Metab 2(4):339-354.
2. Yanagida O, Kanai Y, Chairoungdua A, Kim DK, Segawa H, Nii T, Cha SH, Matsuo H, Fukushima J, Fukasawa Y, Tani Y, Taketani Y, Uchino H, Kim JY, Inatomi J, Okayasu I, Miyamoto K, Takeda E, Goya T, Endou H. 2001. Human L-type amino acid transporter 1 (LAT1): Characterization of function and expression in tumor cell lines. Biochim Biophys Acta 1514(2):291-302.
3. Kanai Y, Segawa H, Miyamoto K, Uchino H, Takeda E, Endou H. 1998. Expression cloning and characterization of a transporter for large neutral amino acids activated by the heavy chain of 4F2 antigen (CD98). J Biol Chem 273(37):23629-23632.
4. Prasad PD, Wang H, Huang W, Kekuda R, Rajan DP, Leibach FH, Ganapathy V. 1999. Human LAT1, a subunit of system L amino acid transporter: Molecular cloning and transport function. Biochem Biophys Res Commun 255(2):283-288.
5. Kaira K, Oriuchi N, Shimizu K, Imai H, Tominaga H, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Oyama T, Mori M, Endo K. 2010. Comparison of L-type amino acid transporter 1 expression and L-[3-18F]-alpha-methyl tyrosine uptake in outcome of non-small cell lung cancer. Nucl Med Biol 37(8):911-916.
6. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. 2009. L-type amino acid transporter 1 (LAT1) is frequently expressed in thymic carcinomas but is absent in thymomas. J Surg Oncol 99(7):433-438.
7. Sakata T, Ferdous G, Tsuruta T, Satoh T, Baba S, Muto T, Ueno A, Kanai Y, Endou H, Okayasu I. 2009. L-type amino-acid transporter 1 as a novel biomarker for high-grade malignancy in prostate cancer. Pathol Int 59(1):7-18.
8. Kim DK, Ahn SG, Park JC, Kanai Y, Endou H, Yoon JH. 2004. Expression of L-type amino acid transporter 1 (LAT1) and 4F2 heavy chain (4F2hc) in oral squamous cell carcinoma and its precursor lesions. Anticancer Res 24(3a):1671-1675.
9. Ichinoe M, Mikami T, Yoshida T, Igawa I, Tsuruta T, Nakada N, Anzai N, Suzuki Y, Endou H, Okayasu I. 2011. High expression of L-type amino-acid transporter 1 (LAT1) in gastric carcinomas: Comparison with non-cancerous lesions. Pathol Int 61(5):281-289.
10. Nawashiro H, Otani N, Shinomiya N, Fukui S, Ooigawa H, Shima K, Matsuo H, Kanai Y, Endou H. 2006. L-type amino acid transporter 1 as a potential molecular target in human astrocytic tumors. Int J Cancer 119(3):484-492.
11. Kaira K, Oriuchi N, Imai H, Shimizu K, Yanagitani N, Sunaga N, Hisada T, Tanaka S, Ishizuka T, Kanai Y, Endou H, Nakajima T, Mori M. 2008. Prognostic significance of L-type amino acid transporter 1 expression in resectable stage I-III nonsmall cell lung cancer. Br J Cancer 98(4):742-748.
12. Oriuchi N, Higuchi T, Ishikita T, Miyakubo M, Hanaoka H, Iida Y, Endo K. 2006. Present role and future prospects of positron emission tomography in clinical oncology. Cancer Sci 97(12):1291-1297.
13. Kim CH, Park KJ, Park JR, Kanai Y, Endou H, Park JC, Kim do K. 2006. The RNA interference of amino acid transporter LAT1 inhibits the growth of KB human oral cancer cells. Anticancer Res 26(4B):2943-2948.
14. Kim CS, Cho SH, Chun HS, Lee SY, Endou H, Kanai Y, Kim do K. 2008. BCH, an inhibitor of system L amino acid transporters, induces apoptosis in cancer cells. Biol Pharm Bull 31(6):1096-1100.
15. Oda K, Hosoda N, Endo H, Saito K, Tsujihara K, Yamamura M, Sakata T, Anzai N, Wempe MF, Kanai Y, Endou H. 2009. L-type amino acid transporter 1 inhibitors inhibit tumor cell growth. Cancer Sci 101(1):173-179.
16. Wempe MF, Rice PJ, Lightner JW, Jutabha P, Hayashi M, Anzai N, Wakui S, Kusuhara H, Sugiyama Y, Endou H. 2012. Metabolism and pharmacokinetic studies of JPH203, an l-amino acid transporter 1 (LAT1) selective compound. Drug Metab Pharmacokinet 27(1):155-161.
17. Debiec-Rychter M, Land SJ, King CM. 1999. Histological localization of acetyltransferases in human tissue. Cancer Lett 143(2):99-102.
18. Kusama M, Toshimoto K, Maeda K, Hirai Y, Imai S, Chiba K, Akiyama Y, Sugiyama Y. 2010. In silico classification of major clearance pathways of drugs with their physiochemical parameters. Drug Metab Dispos 38(8):1362-1370.
19. Maeda K, Sugiyama Y. 2008. Impact of genetic polymorphisms of transporters on the pharmacokinetic, pharmacodynamic and toxicological properties of anionic drugs. Drug Metab Pharmacokinet 23(4):223-235.
20. International Transporter C, Giacomini KM, Huang SM, Tweedie DJ, Benet LZ, Brouwer KL, Chu X, Dahlin A, Evers R, Fischer V, Hillgren KM, Hoffmaster KA, Ishikawa T, Keppler D, Kim RB, Lee CA, Niemi M, Polli JW, Sugiyama Y, Swaan PW, Ware JA, Wright SH, Yee SW, Zamek-Gliszczynski MJ, Zhang L. 2010. Membrane transporters in drug development. Nat Rev Drug Discov 9(3):215-236.
21. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2004. Contribution of OATP2 (OATP1B1) and OATP8 (OATP1B3) to the hepatic uptake of pitavastatin in humans. J Pharmacol Exp Ther 311(1):139-146.
22. Deguchi T, Kusuhara H, Takadate A, Endou H, Otagiri M, Sugiyama Y. 2004. Characterization of uremic toxin transport by organic anion transporters in the kidney. Kidney Int 65(1):162-174.
23. Lowry OH, Rosebrough NJ, Farr AL, Randall RJ. 1951. Protein measurement with the Folin phenol reagent. J Biol Chem 193(1):265-275.
24. Yamaoka K, Tanigawara Y, Nakagawa T, Uno T. 1981. A pharmacokinetic analysis program (multi) for microcomputer. J Pharmacobiodyn 4(11):879-885.
25. Hirano M, Maeda K, Shitara Y, Sugiyama Y. 2006. Drug-drug interaction between pitavastatin and various drugs via OATP1B1. Drug Metab Dispos 34(7):1229-1236.
26. Watanabe T, Kusuhara H, Maeda K, Kanamaru H, Saito Y, Hu Z, Sugiyama Y. 2010. Investigation of the rate-determining process in the hepatic elimination of HMG-CoA reductase inhibitors in rats and humans. Drug Metab Dispos 38(2):215-222.
27. Watanabe T, Maeda K, Kondo T, Nakayama H, Horita S, Kusuhara H, Sugiyama Y. 2009. Prediction of the hepatic and renal clearance of transporter substrates in rats using in vitro uptake experiments. Drug Metab Dispos 37(7):1471-1479.
28. Hein DW. 2002. Molecular genetics and function of NAT1 and NAT2: Role in aromatic amine metabolism and carcinogenesis. Mutat Res 506-507:65-77.
29. Kim YG, Shin JG, Shin SG, Jang IJ, Kim S, Lee JS, Han JS, Cha YN. 1993. Decreased acetylation of isoniazid in chronic renal failure. Clin Pharmacol Ther 54(6):612-620.
30. Kinzig-Schippers M, Tomalik-Scharte D, Jetter A, Scheidel B, Jakob V, Rodamer M, Cascorbi I, Doroshyenko O, Sorgel F, Fuhr U. 2005. Should we use N-acetyltransferase type 2 genotyping to personalize isoniazid doses? Antimicrob Agents Chemother 49(5):1733-1738.
31. Ieiri I, Doi Y, Maeda K, Sasaki T, Kimura M, Hirota T, Chiyoda T, Miyagawa M, Irie S, Iwasaki K, Sugiyama Y. 2012. Microdosing clinical study: Pharmacokinetic, pharmacogenomic (SLCO2B1), and interaction (grapefruit juice) profiles of celiprolol following the oral microdose and therapeutic dose. J Clin Pharmacol 52(7):1078-1089.
32. Kusuhara H, Furuie H, Inano A, Sunagawa A, Yamada S, Wu C, Fukizawa S, Morimoto N, Ieiri I, Morishita M, Sumita K, Mayahara H, Fujita T, Maeda K, Sugiyama Y. 2012. Pharmacokinetic interaction study of sulfasalazine in healthy subjects and the impact of curcumin as an in vivo inhibitor of BCRP. Br J Pharmacol 166(6):1793-1803.
33. Kobayashi D, Nozawa T, Imai K, Nezu J, Tsuji A, Tamai I. 2003. Involvement of human organic anion transporting polypeptide OATP-B (SLC21A9) in pH-dependent transport across intestinal apical membrane. J Pharmacol Exp Ther 306(2):703-708.